Status:
COMPLETED
Observational Study of Pergolide Mesylate and Cardiac Valvulopathy
Lead Sponsor:
Eli Lilly and Company
Conditions:
Parkinson Disease
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of this study is to estimate the incidence of new-onset valvulopathy, determined by baseline and follow-up echocardiograms, in patients with Parkinson's Disease who are receiving...
Eligibility Criteria
Inclusion
- Male or female, age 18 and older with a diagnosis of Parkinson's Disease
- Receiving pergolide as second-line therapy as prescribed by Summary of Product Characteristics
- Willing to participate and sign a consent to release medical information
- Have had an echocardiogram within 3 months of initiation of pergolide therapy with no evidence of cardiac valvulopathy
Exclusion
- There are no exclusion criteria for this study
Key Trial Info
Start Date :
March 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2007
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00311532
Start Date
March 1 2006
End Date
May 1 2007
Last Update
July 18 2007
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Antwerp, Belgium, 2020
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Edegem, Belgium, 2650
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Ghent, Belgium, 9000
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Montigny-le-Tilleul, Belgium, 6110